Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency

American Journal of Kidney Diseases

Volumn 37, Issue 3, 2001, Pages 484-489

  Tonelli, Marcello ^a,b,c,d   Bohm, Clara ^a,b,c,d   Pandeya, Sanjaya ^a,b,c,d   Gill, John ^a,b,c,d   Levin, Adeera ^a,b,c,d   Kiberd, Bryce A ^a,e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Division of Nephrology   (Canada)

Author keywords

Cardiovascular disease (CVD); Chronic renal failure; Hyperlipidemia; Hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; RISK FACTOR; SMOKING;

EID: 0035127168     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.22070     Document Type: Article

References (30)

1. Clinical epidemiology of cardiovascular disease in chronic renal disease
2. Cardiovascular disease and chronic renal disease: A new paradigm
3. Controlling the epidemic of cardiovascular disease in chronic renal disease: Report from the National Kidney Foundation Task Force on Cardiovascular Disease
4. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
5. Marked reduction in long-term cardiac deaths with aspirin after a coronary event
6. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction
7. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
9. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
10. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
11. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
12. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
13. Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start?
14. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
15. 1999 Canadian recommendations for the management of hypertension including case-based applications of the recommendations
16. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
17. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency
18. Prevalence and correlates of elevated serum creatinine levels: The Framingham Heart Study
19. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus
20. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy
21. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
22. Hyperlipidemia in patients with chronic renal disease
23. Epidemiology of cardiovascular disease in chronic renal disease
24. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
25. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease
26. Audit of antihypertensive treatment in patients with renal failure
27. Effects of aspirin treatment on survival in noninsulin-dependent diabetic patients with coronary artery disease
28. Hyperglycemia and intensive glycemic control in diabetic patients with chronic renal disease